solanezumab: Clinical Trials

5 trials of solanezumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 active not recruiting. 5 Phase 2, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 25Completed 4, Active not recruiting 1
Phase 32Active not recruiting 1, Completed 1

Follow solanezumab: new trials by email Literature Review of solanezumab trials Research Report on solanezumab

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab) - Alzheimers Disease, Dementia
Phase 2 / Phase 3CompletedWashington University School of Medicine1942012-12-012022-09-22
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab) - Alzheimers Disease, Dementia
Phase 2 / Phase 3Active not recruitingWashington University School of Medicine4902012-12-012026-11-19
A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's
solanezumab - Alzheimer's Disease
Phase 2CompletedEli Lilly and Company552010-08-012012-09-25
Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease
Solanezumab - Alzheimer's Disease
Phase 2CompletedEli Lilly and Company332008-09-012010-06-02
Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers
LY2062430, Placebo - Alzheimer's Disease
Phase 2CompletedEli Lilly and Company252006-05-012009-10-07

Conditions studied

Alzheimer Disease (5)  ·  Dementia (2)

Sponsors

Eli Lilly and Company (3)  ·  Washington University School of Medicine (2)

Countries

United States (4)  ·  Australia (2)  ·  Canada (2)  ·  France (2)  ·  Ireland (2)  ·  Japan (2)  ·  Puerto Rico (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Argentina (1)  ·  Brazil (1)  ·  Colombia (1)  ·  Germany (1)  ·  Italy (1)  ·  Netherlands (1)

Top investigators

Randall J Bateman, MD (2)

Results publications

PMID 36110925, PMID 37017737, PMID 38683602, PMID 39974075, PMID 40120616, PMID 40985290

NIH funding

R01AG046179 (2), U01AG042791 (2), R01AG053267 (1), R56AG053267 (1), U01AG059798 (1)